Dare Bioscience, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Dare Bioscience, Inc. on April 7, 2021. The company, incorporated in Delaware and trading on the Nasdaq Capital Market under the symbol "DARE," reported the entry into a material definitive agreement on this date.
Key Financial Metrics
The filing does not provide specific financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity for a reporting period. The document focuses exclusively on the authorization of a new equity offering program.
Material Changes and Agreements
On April 7, 2021, Dare Bioscience entered into a Sales Agreement with SVB Leerink LLC to establish an "at-the-market" (ATM) equity offering program. Key terms include:
- Offering Size: The company may issue and sell up to $50,000,000 of its common stock.
- Sales Agent: SVB Leerink LLC will act as the agent for sales.
- Commission: The company agreed to pay a commission of 3.0% of the gross proceeds from sales.
- Flexibility: The company retains the right to set sales parameters, including price floors and daily volume limits, and may suspend or terminate the agreement with five days' notice.
- Registration: Shares will be issued pursuant to a shelf registration statement on Form S-3 declared effective on April 7, 2021.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on operational outlook, or specific risk factors beyond standard legal disclaimers. The company noted that it has no obligation to sell any shares under the agreement and may do so at its sole discretion. The document explicitly states that the Sales Agreement is not intended to provide factual information about the company's current state of affairs.
Investor Verification Checklist
- Verify the current share price and trading volume to assess the potential dilution impact of the $50,000,000 ATM program.
- Review the company's most recent 10-K or 10-Q filings for actual cash position and liquidity needs driving this offering.
- Monitor future 8-K filings to determine if and when shares are actually sold under this agreement.
- Confirm the status of the Form S-3 shelf registration (File No. 333-254862) for any subsequent amendments.